Patent US2433765A successfully refreshed from Google Patents.
Patent US5651985A successfully refreshed from Google Patents.
US5651985A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Expandable pharmaceutical forms
Assignee: Bayer Intellectual Property GmbH
•
Filing: 1995-02-21
•
Granted: 1997-07-29
•
Expires: 2015-02-21
Abstract
Abstract The present invention relates to administration forms having an extended gastric residence time, in the preparation of which mixtures of polymers containing lactam groups and polymers containing carboxyl groups are used, and which are distinguished both by marked swelling properties and by high dimensional stability in the swollen state.
Inventors
- 👤 Gunther Penners
- 👤 Klemens Lustig
- 👤 Jorg Petersen-von Gehr
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 17:58
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/0065; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/2072; A61K9/2086; A61P; A61P31/00; A61P31/04
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
154 words
A pharmacologically active composition in a physical form imparting a prolonged gastric residence time, said physical form being selected from the group consisting of tablets, capsules, granules and pellets, said composition comprising: (I) at least one pharmacologically active compound, (II) at least one pharmacologically acceptable auxiliary, (III) polyvinylpyrrolidone, (IV) a methacrylic acid polymer having an acidic number between 100 and 1,200 mg of KOH/g of polymer solid substance, and (V) optionally a gas-forming additive, the polymers (IIl) and (IV) being present in the form of a homogeneous mixture on the molecular level, the mixture being present in 30-90% by weight of the composition, the weight ratio of (III):(IV) ranging from 80:20 to 95:5, and the composition in dry compressed state being able to absorb many times its weight of acidic water thereby to form a highly swollen gel of high mechanical and dimensional stability capable of improved prolonged release of the pharmacologically active compound.
Claim 2
Dependent Claim
154 words
A pharmacologically active composition in a physical form imparting a prolonged gastric residence time, said physical form being selected from the group consisting of tablets, capsules, granules and pellets, said composition comprising: (I) at least one pharmacologically active compound, (II) at least one pharmacologically acceptable auxiliary, (III) polyvinylpyrrolidone, (IV) a methacrylic acid polymer having an acidic number between 100 and 1,200 mg of KOH/g of polymer solid substance, and (V) optionally a gas-forming additive, the polymers (IIl) and (IV) being present in the form of a homogeneous mixture on the molecular level, the mixture being present in 30-90% by weight of the composition, the weight ratio of (III):(IV) ranging from 80:20 to 95:5, and the composition in dry compressed state being able to absorb many times its weight of acidic water thereby to form a highly swollen gel of high mechanical and dimensional stability capable of improved prolonged release of the pharmacologically active compound.
Claim 3
Dependent Claim
59 words
A tablet according to claim 1, wherein the active compound (I) comprises at least one compound selected from the group consisting of ciprofloxacin, nimodipine, captopril, ranitidine, cyclosporin, baclofen, allopurinol, furosemide, cefoxitine, 5-aminosalicylate and moexipril, and the polymer (IV) is a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups:ester groups from 1:1 to 1:2.
Claim 4
Dependent Claim
39 words
A tablet according to claim 1, wherein the active compound (I) is an antacid and the polymer (IV) is a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups:ester groups from 1:1 to 1:2.
Claim 5
Dependent Claim
46 words
A tablet according to claim 1, wherein the active compound (I) comprises at least one of magnesium hydroxide and magnesium trisilicate, and the polymer (IV) is a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups:ester groups from 1:1 to 1:2.
Claim 6
Dependent Claim
21 words
A tablet according to claim 1, wherein the active compound (I) comprises at least one of magnesium hydroxide and magnesium trisilicate.
Claim 7
Dependent Claim
38 words
A tablet according to claim 1, wherein the active compound (I) comprises ciprofloxacin and the polymer (IV) is a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups:ester groups from 1:1 to 1:2.
References Cited (Backward Citations)
US3458622A
Cited
US3574820A
Cited
USRE27107E
Cited
US3634584A
Cited
US3976764A
Cited
US4167558A
Cited
US4101650A
Cited
US4434153A
Cited
US4547359A
Cited
EP0235718A2
Cited
EP0250038A2
Cited
US4971805A
Cited
EP0326816A1
Cited
US5158777A
Cited
WO1993000889A1
Cited
US5167964A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-07-28 | 2001-01-27 | 2001-07-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-07-28 | 2005-01-27 | 2005-07-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-07-28 | 2009-01-27 | 2009-07-29 | $7700.00 | Window Closed / Lapsed |